Hutchinson S, et al. Rimegepant 75 mg demonstrates safety and tolerability similar to placebo: results from 3 phase 3 trials in adults with migraine. Abstract IHC-PO-133. IHC 2019 5-8 sept. Dublin, Ierland.
MS: COVID-19, uitgesteld doseren natalizumab en nieuwe middelen
dec 2020 | Multipele Sclerose